{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-25-000114","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.419865+00:00","generated_at":"2026-05-17T01:18:21.217245+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Agios Q3 PYRUKYND rev $12.9M (+44% YoY); net loss $103.4M; thalassemia PDUFA Dec 7","bullets":["Q3 PYRUKYND net revenue $12.9M (+44% YoY vs $9.0M); 149 U.S. patients on therapy.","Net loss $103.4M in Q3 2025 vs net income $947.9M in Q3 2024 (prior-year milestone payments).","Cash $1.3B; PDUFA goal date Dec 7, 2025 for PYRUKYND sNDA in thalassemia.","CHMP positive opinion for PYRUKYND in thalassemia; EC decision expected early 2026.","RISE UP Phase 3 sickle cell disease topline results by year-end; tebapivat Phase 2b topline early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-25-000114","json":"https://secwatch.observer/filing/0001439222-25-000114.json","markdown":"https://secwatch.observer/filing/0001439222-25-000114.md","text":"https://secwatch.observer/filing/0001439222-25-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/0001439222-25-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/agio-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:18:21.217245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}